Sensorion announces that the research partnership framework agreement signed in 2019 with the Institut Pasteur granting Sensorion an option for exclusive licenses to develop and market gene therapy drug candidates from collaborative projects to address unmet medical needs in the hearing field has been extended for a period of five years.
